CytomX | 8-K: Current report
CytomX | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BVF Partners L.P.(9.99%),BVF Inc.(9.99%), etc.
CytomX | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Tang Capital Management, LLC(9.99%),Kevin Tang(9.99%), etc.
CytomX | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Cormorant Asset Management, LP(0%),Bihua Chen(0%)
CytomX | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(6.2%),Janus Henderson Biotech Innovation Master Fund Ltd(6.2%)
CytomX | 8-K: CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
CytomX | 10-Q: Q3 2024 Earnings Report
CytomX | 4: Statement of changes in beneficial ownership of securities-Officer Landau Jeffrey B
CytomX | 4: Statement of changes in beneficial ownership of securities-Officer BELVIN MARCIA
CytomX | 4: Statement of changes in beneficial ownership of securities-Officer ROWLAND LLOYD A
CytomX | 4: Statement of changes in beneficial ownership of securities-Officer Ogden Christopher
CytomX | 4: Statement of changes in beneficial ownership of securities-Officer McCarthy Sean A.
CytomX | EFFECT: Others
CytomX | CORRESP: CORRESP
CytomX | UPLOAD: Others
CytomX | S-3: Registration statement for specified transactions by certain issuers
CytomX | 10-Q: Q2 2024 Earnings Report
CytomX | 8-K: CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
CytomX | 8-K: Current report
CytomX | 4: Statement of changes in beneficial ownership of securities-Officer Ogden Christopher